Respect for Human Rights

Kirin Group Human Rights Policy

The Kirin Group, to which the Kyowa Kirin Group belongs, has formulated the Kirin Group Human Rights Policy based on the UN "Guiding Principles on Business and Human Rights." By promoting management that values human rights in both Japan and overseas, we at the Kyowa Kirin Group aim to further contribute to the development of a sustainable society as a member of the Kirin Group.

Raising Human Rights Awareness

Our activities to raise employee awareness of human rights are based on the policies and measures determined by the Kirin Group Human Rights Promotion Committee*1, in which Kyowa Kirin participates as a member. Our human rights awareness building program, for example, was launched in 2009, and has also been introduced at Kyowa Kirin Group companies. Moreover, awareness building programs on LGBT (lesbian, gay, bisexual and transgender) issues are also offered. In July 2017, we established the Kyowa Kirin Group Human Rights Promotion Committee*2 with the aim of raising employee awareness of the importance of human rights throughout the Group.

Other efforts to raise human rights awareness include conducting the Kirin Group Compliance/Human Rights Awareness Survey in conjunction with all other Kirin Group companies; sharing a message from the president to employees during Harassment Elimination Month; and soliciting slogans from employees for Human Rights Week. We have also established an internal reporting contact, where employees can call to report or seek advice on harassment and other human rights issues. Such efforts are aimed at eliminating harassment from workplaces and enhancing the corporate culture.

In addition, we are a member of the Business Ethics Research Center, and participate in the Harassment Study Group and the Diversity Management Study Group to acquire relevant knowledge and improve understanding.

  1. *1:
    A committee chaired by the human resources director of Kirin Holdings and staffed by human resources department managers from major companies within the Kirin Group.
  2. *2:
    A committee chaired by the director of Kyowa Kirin's Human Resources Department and staffed by human resources department managers from major subsidiaries of Kyowa Kirin.

Ensuring Human Rights throughout Our Value Chain

Kyowa Kirin is endeavoring to ensure human rights throughout its pharmaceutical value chain.

Human rights considerations in research

Kyowa Kirin sets internal rules with the aim of assuring ethical and scientific validity in human genome analysis and research using human tissue as well as preventing the loss of dignity and protecting the human rights of tissue donors.

Ethical Considerations in Research and DevelopmentOpen in new window

Safeguarding human rights in clinical trials

When conducting a clinical trial involving human subjects, Kyowa Kirin, pursuant to the Declaration of Helsinki, gives top priority to protecting the human rights and personal information of patients participating in the trial, securing their safety, and giving consideration to their welfare, and complies with the laws and regulations and Good Clinical Practices (GCP) guidelines of the applicable countries.

Clinical Research PolicyOpen in new window

Ensuring human rights in purchasing activities

We have formulated the "Kyowa Kirin Group Procurement Policy" and the "Kyowa Kirin CSR Procurement Guidebook" to help us ensure human rights throughout the supply chain in collaboration with our suppliers.

CSR Procurement (Initiatives for the supply chain)Open in new window

Ensuring human rights in production activities

We have established the "Kyowa Kirin Group Policy for Occupational Health and Safety" with the aim of securing the safety of our employees. Policy for Occupational Health and Safety

Basic Policy on the Environment, Safety and Product SafetyOpen in new window

Ensuring human rights in engaging with medical institutions and patient organizations

Pursuant to the Kyowa Kirin Group Compliance Policy, we act with high ethical standards and in the best interest of patients when we engage with medical institutions and patient organizations.

TransparencyOpen in new window